Study shows semaglutide reduces BMI in obese children aged six and older
Read more
N+1
nplus1.ru

Study shows semaglutide reduces BMI in obese children aged six and older

Results from phase three clinical trials conducted by researchers from five different countries demonstrated the effectiveness of the drug semaglutide in reducing the body mass index in children suffering from obesity aged six to eleven years. Furthermore, the drug showed an acceptable safety profile.

Information on the progress of these trials was officially published in the scientific journal The New England Journal of Medicine.

Similar stories

Ribapatide, a dual agonist of GLP and GIP, showed effectiveness in reducing body weight in obesity
Read more
nplus1.ru

Ribapatide, a dual agonist of GLP and GIP, showed effectiveness in reducing body weight in obesity

The study showed that ribapatide, which is a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, is capable of significantly reducing body weight in people with obesity.

When this substance was used at a dosage of six milligrams weekly for 48 weeks, a body weight reduction of 17.7 percent was observed. Furthermore, in a randomized clinical trial conducted in China, 85.7 percent of participants experienced a weight loss of at least five percent.

The results of this scientific work were officially published in The Journal of the American Medical Association.

Researchers present results of tirzepatide trials for weight loss in obese adolescents
Read more
nplus1.ru

Researchers present results of tirzepatide trials for weight loss in obese adolescents

A team of American, Israeli, and Indian scientists has published data obtained during the third phase of clinical trials for the drug tirzepatide. These studies aimed to investigate the effectiveness of tirzepatide in reducing body weight in adolescents suffering from obesity.

According to the presented results, over a period of 72 weeks, the average reduction in body mass index among participants taking the drug was nearly 20% compared to the placebo group. Furthermore, it was noted that the side effects registered during the trials were mild and consistent with predictions.

The full report on the conducted trials was officially published in the scientific journal JAMA: The Journal of the American Medical Association.

MIT Researchers Improve Qwen3.5-0.8B Model by Modifying GPT-6 Astra Weights
Read more
nplus1.ru

MIT Researchers Improve Qwen3.5-0.8B Model by Modifying GPT-6 Astra Weights

Researchers from MIT CSAIL conducted an experiment demonstrating the possibility of improving one language model by directly modifying the weights of another model. In early November, they showed that the GPT-6 Astra model was able to significantly enhance the mathematical capabilities of Qwen3.5-0.8B.

This improvement was achieved without the need for standard fine-tuning. Instead, the researchers boosted performance by adjusting only hundredths of a percent of the weights of the Qwen3.5-0.8B model.

Popular